Manual SAE monitoring is a high-stakes operational bottleneck, relying on clinical staff to spot critical safety signals across fragmented EDC, lab, and patient-reported data. This reactive process delays regulatory reporting, increases compliance risk, and ties up pharmacovigilance teams in data sifting. A custom automated workflow replaces this with continuous, algorithm-driven surveillance, detecting potential SAEs in near real-time. The business value is clear: faster detection reduces patient risk, accelerates mandatory reporting to meet FDA/EMA deadlines, and reallocates PV analyst effort from search to high-value case assessment and medical review.




